Roche Alzheimer’s antibody fails to slow cognitive decline in major test
Results of phase 3 trials testing gantenerumab are latest blow to amyloid hypothesis The second (and third) time was not the charm for Roche’s experimental antibody drug for Alzheimer’s disease. The company last night announced gantenerumab had failed to show a statistically significant benefit in two large, late-stage clinical trials that tested its ability to…